Literature DB >> 3139316

Pharmacokinetics of thio-TEPA at two different doses.

B Hagen1, R A Walstad, O G Nilsen.   

Abstract

Thio-TEPA pharmacokinetics were studied at doses of 20 mg and 30 mg in six patients treated for ovarian cancer. Considerable interindividual variation was encountered in its pharmacokinetics, which were dose-independent within the dose range studied and similar to those reported at far higher doses. Interindividual dosing of thio-TEPA based on an initial AUC estimation is suggested.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3139316     DOI： 10.1007/bf00254246

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  9 in total

1.  Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolites.

Authors:  B E Cohen; M J Egorin; E A Kohlhepp; J Aisner; P L Gutierrez
Journal:  Cancer Treat Rep       Date:  1986-07

2.  Gas chromatographic assay of triethylenethiophosphoramide in serum and urine.

Authors:  B Hagen; F Walseth; R A Walstad; T Iversen
Journal:  J Chromatogr       Date:  1985-11-29

Review 3.  Anticancer drug pharmacodynamics.

Authors:  G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  One-day VATH (vinblastine, Adriamycin, thiotepa, and Halotestin) therapy for advanced breast cancer refractory to chemotherapy.

Authors:  R D Hart; M Perloff; J F Holland
Journal:  Cancer       Date:  1981-10-01       Impact factor: 6.860

5.  Treatment of neoplastic meningitis with intraventricular thiotepa and methotrexate.

Authors:  D L Trump; S A Grossman; G Thompson; K Murray; M Wharam
Journal:  Cancer Treat Rep       Date:  1982-07

6.  A phase I-II study of bialkylator chemotherapy, high-dose thiotepa, and cyclophosphamide with autologous bone marrow reinfusion in patients with advanced cancer.

Authors:  S F Williams; J D Bitran; L Kaminer; C Westbrook; R Jacobs; J Ashenhurst; E Robin; S Purl; J Beschorner; C Schroeder
Journal:  J Clin Oncol       Date:  1987-02       Impact factor: 44.544

7.  Single and repeated dose pharmacokinetics of thio-TEPA in patients treated for ovarian carcinoma.

Authors:  B Hagen; F Walseth; R A Walstad; T Iversen; O G Nilsen
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

8.  Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design.

Authors:  H Zincke; R C Benson; J F Hilton; W F Taylor
Journal:  J Urol       Date:  1985-12       Impact factor: 7.450

9.  In vitro sensitivity of human ovarian tumours to chemotherapeutic agents.

Authors:  A P Wilson; F E Neal
Journal:  Br J Cancer       Date:  1981-08       Impact factor: 7.640
  9 in total
  7 in total

1.  Long-term pharmacokinetics of thio-TEPA, TEPA and total alkylating activity following i.v. bolus administration of thio-TEPA in ovarian cancer patients.

Authors:  B Hagen; G Neverdal; R A Walstad; O G Nilsen
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Pharmacokinetics of thio-TEPA and TEPA in the conventional dose-range and its correlation to myelosuppressive effects.

Authors:  B Hagen
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

3.  Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy.

Authors:  A D Huitema; R A Mathôt; M M Tibben; J H Schellens; S Rodenhuis; J H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

4.  Phase I and pharmacokinetic study of intraperitoneal thioTEPA in patients with ovarian cancer.

Authors:  C Lewis; N Lawson; E M Rankin; G Morrison; A B MacLean; J Cordiner; J Cassidy; D J Kerr; S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Integrated Population Pharmacokinetic Model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction.

Authors:  Milly E de Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-04       Impact factor: 2.745

6.  Dosing of thioTEPA for myeloablative therapy.

Authors:  D Przepiorka; T Madden; C Ippoliti; Z Estrov; M Dimopoulos
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

7.  Pharmacokinetics of thiotepa in high-dose regimens for autologous hematopoietic stem cell transplant in Japanese patients with pediatric tumors or adult lymphoma.

Authors:  Eisei Kondo; Takashi Ikeda; Hiroaki Goto; Momoko Nishikori; Naoko Maeda; Kimikazu Matsumoto; Hideo Kitagawa; Naoto Noda; Saori Sugimoto; Junichi Hara
Journal:  Cancer Chemother Pharmacol       Date:  2019-08-19       Impact factor: 3.333
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.